For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new ...
Nov 21, 2023
0
37
Each year antimicrobial resistance—the ability of microbes to survive agents designed to kill them— claims more lives than malaria and HIV/Aids combined. Africa bears the brunt of this development, which thrives on inequality ...
Nov 21, 2023
0
1
A new study out this week in the journal Social Science and Medicine proposes that social, gendered variables may better explain observed sex disparities in adverse drug events than sex-based biology.
Nov 14, 2023
0
0
While the overall cancer death rate has been steadily declining in the U.S. since the 1990s, death rates due to pancreatic cancer are increasing.
Nov 8, 2023
0
0
In science, a simple but thorough observation can kick-start the most surprising findings. Researchers at the MUSC Hollings Cancer Center noticed that mice lacking a protein of interest in cancer research were showing visible ...
Nov 7, 2023
0
34
Every organism needs to breathe—including cells that we use in in vitro microphysiological systems. We now have promising results with a material that enhances the quality of our experiments.
Oct 25, 2023
0
0
Of the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% were precision oncology therapies, the use of which is guided by biomarker testing.
Oct 18, 2023
0
0
Researchers at the University of Oulu have made a discovery in breast cancer research. They demonstrated that the extracellular matrix protein collagen XVIII significantly promotes breast cancer progression and metastasis. ...
Oct 17, 2023
0
1
Cancer research has long focused on targeting the genetic mutations that drive tumors. Many of these genetic changes affect genes that allow mutated cells to replicate out of control. While developing drugs to target these ...
Oct 16, 2023
0
20
A new research paper titled "Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells" has been published in Oncotarget.
Oct 11, 2023
0
0
